Press release
Biopharma PEG Announces FDA DMF Registration for mPEG-pAld (20K)
"We are thrilled to receive FDA DMF registration for our mPEG-pAld (20K) product," said Sonia Lee, Marketing Director at Biopharma PEG. "This achievement demonstrates our commitment to providing our customers with the highest quality materials for their drug development programs. We are confident that this registration will help to streamline and accelerate the development of new drugs."
mPEG-pAld (20K) is a monomethoxy poly(ethylene glycol) derivative with a p-aldehyde functional group. It is a versatile building block that can be used in a variety of applications, including:
• Drug conjugation
• Targeted drug delivery
• Bioconjugation
• Biomaterials science
Why Choose Biopharma PEG?
• Exceptional Purity and Consistency: Biopharma PEG's strict quality controls guarantee high purity and reliable batch-to-batch consistency, meeting global standards.
• Regulatory Expertise: FDA DMF certification ensures full regulatory support to streamline and accelerate drug development.
• GMP Standards: GMP-compliant production with support from R&D to kilogram-scale manufacturing, meeting diverse needs.
"We are committed to providing our customers with the best possible products and services," said Ms. Lee. "We look forward to working with our customers to bring new and innovative drugs to market."
Biopharma PEG Scientific Inc.
108 Water Street, Suite 4D, Watertown, MA 02472, USA
TEL: 1-857-928-2050 / 1-857-366-6766
Fax: 617-206-9595
Email: sales@biochempeg.com
Biopharma PEG is a leading manufacturer of high-quality PEG derivatives. The company offers a wide range of PEG products for use in the pharmaceutical, biotechnology, and other industries. Biopharma PEG is committed to providing its customers with exceptional quality products, regulatory expertise, and GMP-compliant manufacturing.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biopharma PEG Announces FDA DMF Registration for mPEG-pAld (20K) here
News-ID: 3819892 • Views: …
More Releases from Biopharma PEG Scientific Inc
FDA Approval of Vepdegestrant Highlights the Growing Importance of Linker Design …
Watertown, MA - The recent FDA approval of vepdegestrant (VeppanuTM, ARV-471) marks a significant milestone for targeted protein degradation, bringing the first PROTAC therapy into clinical practice for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Beyond validating the PROTAC modality, this achievement has renewed attention on one of its most critical design elements-the linker.
Unlike conventional small-molecule inhibitors, PROTACs (Proteolysis Targeting Chimeras) eliminate disease-causing proteins by recruiting an…
Biopharma PEG to Present PEG Derivatives at TIDES USA 2026 in Boston
Biopharma PEG will exhibit at TIDES USA 2026 in Boston this May, where the company will introduce its latest portfolio of high-purity PEG derivatives for drug delivery, bioconjugation, and related pharmaceutical research applications.
The event will be held at the Hynes Convention Center in Boston, Massachusetts, USA, from May 11-14, 2026. Biopharma PEG will welcome visitors at Booth 826 to discuss product selection, application needs, and supply support for research and…
Biopharma PEG Offers In-Stock Monodispersed PEGs at Competitive Prices
Biopharma PEG Scientific Inc. announced the availability of a broad range of in-stock monodispersed PEG derivatives at highly competitive prices, supporting researchers working in antibody-drug conjugates (ADCs), nanoparticle and LNP delivery systems, diagnostics, and biomaterials.
Biopharma PEG specializes in PEG derivatives, including monodispersed, polydispersed, and multi-arm PEGs, offered in both GMP and non-GMP grades. By keeping key monodispersed PEGs on the shelf and ready to ship, the company aims to help…
Biopharma PEG Highlights the Critical Role of PEG-Lipid Nanoparticles in RNA The …
Watertown, MA, September 26, 2025 - In the past decade, lipid nanoparticles (LNPs) have emerged as the premier delivery vehicle for RNA-based medicines, powering the success of both siRNA drugs and mRNA vaccines. A key component of these systems is PEG-lipids, specialized polyethylene glycol (PEG) derivatives that stabilize nanoparticles, extend circulation time, and enhance safety.
Why PEG-Lipids Are Essential
RNA molecules are inherently unstable in the bloodstream, where they are rapidly degraded…
More Releases for DMF
Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval
Changsha, China - Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. This achievement highlights Huateng Pharma's dedication to meeting the highest regulatory standards and further strengthens its commitment to supporting…
Dimethylformamide (DMF) Market Share, Key Market Players, Trends & Forecast, 202 …
New York, United States, - The growth of the Dimethylformamide (DMF) Market is driven by several key factors, including its extensive use as a solvent in various industries and the rising demand for high-performance chemicals in manufacturing processes. DMF is a versatile organic solvent with excellent solvency properties, making it essential in the production of pharmaceuticals, agrochemicals, and synthetic fibers. The pharmaceutical industry, in particular, relies heavily on DMF for…
Global Dimethylformamide (DMF) Market Statistics, Segment, Trends and Forecast t …
Dimethylfomamide (DMF) Market size stood at USD 768.44 Million in 2022 and is projected to reach USD 1,139.09 Million, by 2032. Growing at a CAGR of 13.44% during the forecast period i.e. 2023-2032.
The rising demand for dimethylformamide (DMF) from a variety of end-use sectors, including the chemical, pharmaceutical, electronics, and agrochemical industries, is responsible for the rise of the DMF Market globally. The global dimethylformamide (DMF) market is expanding as…
DMF (Dimethylformamide) Production Cost Analysis Report, Raw Materials Requireme …
The latest report titled "DMF (Dimethylformamide) Production Cost Report" by Procurement Resource, a global procurement research and consulting firm, provides an in-depth cost analysis of the production process of the DMF (Dimethylformamide).
Product Name - DMF (Dimethylformamide)
Process Included - Aluminium Can Production from Two-Piece or Three-Piece Drawing
Currency US$ (Data can also be provided in local currency)
Customization Scope - The report can be customized as per the requirements of the customer
Post-Sale Analyst Support - 360-degree analyst…
DMF Price Chart, Historical and Forecast Analysis Provided by Procurement Resour …
Product Name - DMF
HS Code - 29211110
Molecular Weight - 73.09g/mol
Chemical Formula - C3H7NO
Synonyms - Dimethylformamide, 68-12-2, Dimethyl formamide, N,N-Dimethylmethanamide
Currency - US$ (Data can also be provided in local currency)
Supplier Database Availability - Yes
Customization Scope - Our services can be customized as per the requirements of the customer
Post-Sale Analyst Support - 360-degree analyst support after service delivery
Region/Countries for which Data is available
Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam,…
Global Anhydrous DMF Market to Witness a Pronounce Growth During 2023
New report published by Market Research Report Store (MRRS) which offers insights on the global Anhydrous DMF market.
Click to view the full report TOC, figure and tables:
https://www.marketresearchreportstore.com/reports/212059/global-anhydrous-dmf-market
Global Anhydrous DMF Market: Forecast by Type / Application / Region
According to this study, over the next five years the Anhydrous DMF market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2023, from…
